Clinical Trials Logo

Placenta Accreta clinical trials

View clinical trials related to Placenta Accreta.

Filter by:
  • Recruiting  
  • Page 1 ·  Next »

NCT ID: NCT06383923 Recruiting - Clinical trials for Placenta Accreta Spectrum

Risk Factors, Prognosis and Prediction Models for Placenta Accreta Without Prior Cesarean Section

Start date: January 1, 2023
Phase:
Study type: Observational

1. Identify the risk factors for Placenta accreta spectrum (PAS) disorders in women without prior caesarean section (CS). 2. Clarify the prognostic factors of the disease and explore individualized treatment options to improve the prognosis of patients with this type of disease; 3. Use the cohort's biological sample database to conduct serology, cytology, and histology studies to explore the abnormal uterine immune microenvironment and the impact on uterine spiral artery remodeling in non-scar uterine-placenta accreta disease.

NCT ID: NCT06185894 Recruiting - Placenta Accreta Clinical Trials

The Role of Using Tourniquet in Decreasing Bleeding in Placenta Accreta Spectrum Cases

Start date: October 1, 2023
Phase: N/A
Study type: Interventional

Background: An optimal international standard for PAS surgery is not yet available, and the establishment of a suitable surgical method is an important focus of in PAS management. Objective: To assess the efficacy and safety of tourniquet uses for conservative approach in the management of placenta accerta spectrum. Patients and Methods: 40 pregnant women who underwent conservative management of placenta accrete at Kasr El-Aini hospital (Obstetrics and gynecology department - Faculty of medicine - Cairo university) were included and were divided according to the use of tourniquet into 2 equal groups: Study group (tourniquet group): consists of 20 women for whom tourniquet was used in the lower part of the uterus during surgical treatment of placenta accreta spectrum.Control group (no tourniquet group): consists of 20 women for whom no tourniquet was used.

NCT ID: NCT06030492 Recruiting - Placenta Accreta Clinical Trials

Efficacy of Hydrogen Peroxide ( H2O2) in Controlling Placental Site Bleeding in Caesarian Delivery for Placenta Previa / Accreta Spectrum ( PAS)

Start date: January 1, 2023
Phase: N/A
Study type: Interventional

Placenta accreta spectrum (PAS), encompassing the terms placenta accreta, increta, and percreta; abnormally invasive placenta; morbidly adherent placenta; and invasive placentation, is a leading cause of life-threatening obstetric haemorrage (1) . Currently, more than 90% of women diagnosed with PAS also have a placenta praevia (2), and the combination of both conditions leads to high maternal morbidity and mortality due to massive haemorrhage at the time of birth . Maternal mortality of placenta praevia with percreta has been reported to be as high as 7% of cases . Hydrogen peroxide is well-known for its antimicrobial and antiseptic properties. It is used to clean surgical cuts for better localization of bleeding focus in surgery and orthopedics and burn excisions to induce hemostasis . Topical application of hydrogen peroxide was proven to induce hemostasis and reduce operative time in both tonsillectomy and adenoidectomy .

NCT ID: NCT06030479 Recruiting - Placenta Accreta Clinical Trials

Topical Adrenaline Versus Warm Saline Solution for Minimizing Intraperitoneal Bleeding During Caesarian Delivery for Placenta Previa / Accreta Spectrum ( PAS)

Start date: February 1, 2023
Phase: N/A
Study type: Interventional

Placenta accreta spectrum (PAS), encompassing the terms placenta accreta, increta, and percreta; abnormally invasive placenta; morbidly adherent placenta; and invasive placentation, is a leading cause of life-threatening obstetric haemorrage . Currently, more than 90% of women diagnosed with PAS also have a placenta praevia , and the combination of both conditions leads to high maternal morbidity and mortality due to massive haemorrhage at the time of birth . Maternal mortality of placenta praevia with percreta has been reported to be as high as 7% of cases . Adrenaline has also been demonstrated to be a reasonable hemostatic agent because of its low cost, low risk, powerful vasoconstrictor, and platelet aggregation. Topical use of adrenaline is an effective and reasonable hemostatic agent in tonsillectomy.

NCT ID: NCT05936645 Recruiting - Placenta Accreta Clinical Trials

The Efficacy of a Temporary Sub-Placental Uterine Tourniquet in Minimizing Intraoperative Blood Loss in Management of Placenta Accreta Spectrum Disorder by a Retrograde Cesarean Hysterectomy (Bladder Last)

Start date: August 1, 2023
Phase: N/A
Study type: Interventional

This trial will study the role of a temporary tourniquet around the uterus to reduce blood loss in management of patients with abnormally implanted placenta who will undergo removal of the uterus.

NCT ID: NCT05922397 Recruiting - Placenta Accreta Clinical Trials

Placenta Accreta Spectrum Topographic Classification

Start date: May 21, 2023
Phase:
Study type: Observational

The present study is a prospective multicenter study consisting of a cohort of patients with prenatal or intraoperative diagnosis of PAS, evaluating the clinical outcomes of the group of patients found in each category of the topographic classification. In addition, an approach to evaluate the acceptability of this classification among the obstetrician-gynecologists of the participating medical centers will be included.

NCT ID: NCT05752513 Recruiting - Clinical trials for Placenta Accreta Spectrum

Early vs Late Bladder Dissection During CS Hysterectomy in Patients With PAS With Bladder Invasion

Start date: February 23, 2023
Phase: N/A
Study type: Interventional

Thirty-six singleton pregnant women with PAS and bladder invasion; total anterior or anterolateral invasion, who were scheduled for cesarean hysterectomy were randomly assigned into two equal groups - Group 1: included 18 pregnant women scheduled for classical cesarean hysterectomy for placenta accreta with or without ligation of anterior division of internal iliac artery before cesarean section. - Group 2: included 18 pregnant women scheduled for bladder last cesarean hysterectomy with or without ligation of anterior division of internal iliac artery.

NCT ID: NCT05510076 Recruiting - Clinical trials for Placenta Accreta Spectrum

Evaluation of Different Surgical Approaches Used for Conservative Management of Placenta Accreta Spectrum in Sohag University Hospital

Start date: August 1, 2022
Phase:
Study type: Observational

The objective of this study is to evaluate different intra-operative procedures to control bleeding in cases of PAS disorders aiming to determine the best procedure regarding maternal morbidity and mortality post-operatively, and to evaluate the long-term effects of conservative management of PAS disorders.

NCT ID: NCT05471102 Recruiting - Placenta Accreta Clinical Trials

Ligation of Anterior Internal Iliac Artery With Conservative Management of Partial or Focal Placenta Accreta Spectrum

Start date: July 3, 2022
Phase: N/A
Study type: Interventional

The patients will be divided into 2 groups: Group (A) - Study group: Cases managed by lower segment resection with ligation of the anterior division of the internal iliac artery Group (B) - Control group: Cases managed by lower segment resection without ligation of the anterior division of the internal iliac artery The following operative details will be recorded: - Estimation of total blood loss - Pre and 24-h post-operative hemoglobin (g/dl). - The need for blood transfusion and its amount intra or postoperative will be recorded - Operative time and postoperative hospital stay will be recorded. - Close post-operative monitoring of the patients' vital signs, drain output, and urine output - Presence or absence of intraoperative complications; bladder, ureteric, bowel, or vascular injuries will be recorded. - Monitoring for postoperative morbidities

NCT ID: NCT05376410 Recruiting - Clinical trials for Placenta Accreta, Third Trimester

Relationship Between Maternal Soluble Trigger Receptor Expressed on Myeloid Cells-1 (sTREM-1) and Placenta Accreta Spectrum

Start date: November 14, 2021
Phase:
Study type: Observational

We planed to evaluate soluble the triggering receptors expressed on myeloid cell-1 (s TREM-1) levels in serum of pregnant women diagnosed with placenta accreta spectrum and compare it with healthy pregnant women's s TREM-1 serum levels.